This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Midulla, M. Articles by George, A. J. T. Search for Related Content PubMed PubMed Citation Articles by Midulla, M. Articles by George, A. J. T.

Source of Oncofetal ED-B-containing Fibronectin: Implications of Production by Both Tumor and Endothelial Cells¹

Department of Immunology, Division of Medicine [M. M., R. V., M. A. R., N. S. C-L., A. J. T. G.] and Department of Histopathology, Division of Investigative Science [M. P.], Imperial College School of Medicine, Hammersmith Hospital, London, W12 0NN, United Kingdom; Antisoma plc, West Africa House, Hanger Lane, Ealing, London W5 3QR, United Kingdom [R. V., N. S. C-L.]

ED-B fibronectin (FN) is a FN isoform derived from alternative splicing of the primary transcript of a single gene. Its expression on tumor stroma and neoformed tumor vasculature and its absence, with few exceptions, in normal adult tissues imply a prognostic and diagnostic value for ED-B FN. We investigated the location and source of ED-B FN because this will be of importance both in understanding its role in tumor development and in designing strategies to target this molecule. We have confirmed that ED-B FN is expressed in the majority of breast and colorectal carcinoma tissue samples, with strong immunohistochemical staining around the tumor cells and in the tumor stroma. No staining of tumor neovasculature was seen. ED-B FN is produced by a range of tumor and endothelial (both primary and transformed) cell lines, as detected by reverse transcription-PCR, but is not expressed at the plasma membrane. Strong expression of human ED-B FN is seen in tumor xenografts. These data indicate that neoplastic cells can act as the source of ED-B FN in tumors. The lack of cell surface expression on tumor cell lines has clear implications for the design of therapeutic strategies which target this molecule.

This article has been cited by other articles:

				J. Wels, R. N. Kaplan, S. Rafii, and D. Lyden Migratory neighbors and distant invaders: tumor-associated niche cells Genes & Dev., March 1, 2008; 22(5): 559 - 574. [Abstract] [Full Text] [PDF]

				T. Sandal, K. Valyi-Nagy, V. A. Spencer, R. Folberg, M. J. Bissell, and A. J. Maniotis Epigenetic Reversion of Breast Carcinoma Phenotype Is Accompanied by Changes in DNA Sequestration as Measured by AluI Restriction Enzyme Am. J. Pathol., May 1, 2007; 170(5): 1739 - 1749. [Abstract] [Full Text] [PDF]

				Z. A. Khan, M. Cukiernik, J. R. Gonder, and S. Chakrabarti Oncofetal Fibronectin in Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 287 - 295. [Abstract] [Full Text] [PDF]

				S. L. Schor, I. R. Ellis, S. J. Jones, R. Baillie, K. Seneviratne, J. Clausen, K. Motegi, B. Vojtesek, K. Kankova, E. Furrie, et al. Migration-Stimulating Factor: A Genetically Truncated Onco-Fetal Fibronectin Isoform Expressed by Carcinoma and Tumor-Associated Stromal Cells Cancer Res., December 15, 2003; 63(24): 8827 - 8836. [Abstract] [Full Text] [PDF]

				T. Fukuda, N. Yoshida, Y. Kataoka, R.-i. Manabe, Y. Mizuno-Horikawa, M. Sato, K. Kuriyama, N. Yasui, and K. Sekiguchi Mice Lacking the EDB Segment of Fibronectin Develop Normally but Exhibit Reduced Cell Growth and Fibronectin Matrix Assembly in Vitro Cancer Res., October 1, 2002; 62(19): 5603 - 5610. [Abstract] [Full Text] [PDF]

				L. Gillan, D. Matei, D. A. Fishman, C. S. Gerbin, B. Y. Karlan, and D. D. Chang Periostin Secreted by Epithelial Ovarian Carcinoma Is a Ligand for {alpha}V{beta}3 and {alpha}V{beta}5 Integrins and Promotes Cell Motility Cancer Res., September 15, 2002; 62(18): 5358 - 5364. [Abstract] [Full Text] [PDF]